|
Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, Valdés M, Vicente V, Lip GYH, Marín F. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thromb Haemost. 2017 Jun 27;117(7):1448-1454. doi: 10.1160/TH16-12-0961. Epub 2017 Mar 23. PubMed PMID: 28331926.
AÑO: 2017; IF: 6.681
|
28331926
|
Rivera-Caravaca JM, Esteve-Pastor MA, Roldán V, Marín F, Lip GYH. Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation. Expert Opin Drug Saf. 2017 Sep;16(9):1051-1062. doi: 10.1080/14740338.2017.1351542. Epub 2017 Jul 12. Review. PubMed PMID: 28678553.
AÑO: 2017; IF: 3.156
|
|
Rivera-Caravaca JM, Lip GYH. Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation. Evid Based Med. 2017 Aug;22(4):154-155. doi: 10.1136/ebmed-2017-110764. Epub 2017 Jul 13. PubMed PMID: 28705921.
AÑO: 2017
|
|
Rivera-Caravaca JM, Marín F, Esteve-Pastor MA, Raña-Míguez P, Anguita M, Muñiz J, Cequier Á, Bertomeu-Martínez V, Valdés M, Vicente V, Lip GYH, Roldán V. Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. Am J Cardiol. 2017 Dec 15;120(12):2176-2181. doi: 10.1016/j.amjcard.2017.09.003. Epub 2017 Sep 19. PubMed PMID: 29111209.
AÑO: 2017; IF: 3.171
|
|
Esteve-Pastor MA, Rivera-Caravaca JM, Shantsila A, Roldán V, Lip GYH, Marín F. Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial. Thromb Haemost. 2017 Dec;117(12):2261-2266. doi: 10.1160/TH17-10-0710. Epub 2017 Dec 6. PubMed PMID: 29212113.
AÑO: 2017; IF: 4.952
|